Fredun Pharmaceuticals Ltd — Important, 15-05-2026: Company Update

Fredun Pharmaceuticals confirmed no deviation in utilizing the ₹107.78 Crore raised through its preferential issue for the quarter. This is part of the total ₹149.50 Crore issue. However, the Monitoring Agency could not verify this due to the company's delayed data submission, citing server upgrades and internal process improvements. The Board assured that funds remain for stated objectives and unutilized proceeds are in permitted instruments. Previous concerns about fund parking and loan classifications were clarified as operational management and business-related. Shareholders should note the continued scrutiny on fund deployment.